First patients enrolled in Phase I trial with KQB548, an investigational KRAS inhibitor designed to treat KRAS G12D-mutated tumors
Lonza boosts TheraPEAK line with new Cytokines and AAV Medium for next-gen therapies
Proposed acquisition adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab’s portfolio
The acquisition positions ACL Digital as an end-to-end provider of global clinical research and data CRO solutions
Pfizer will participate in TrumpRx.gov, a direct-to-patient purchasing platform offering discount up to 85%
Sanofi Ventures drives innovation through leading and participating in private financing rounds for pioneering healthcare companies
Amgen has invested over $40 billion in manufacturing and research and development in US since 2017
Alkem's Pertuza is an affordable, indigenously-developed and manufactured biosimilar of pertuzumab
The entity will undertake the installation, operation, and maintenance of sewage treatment plants
Funding supports development of first-in-class pan-ROCK inhibitor ROC-101 through Phase 2a clinical testing
Subscribe To Our Newsletter & Stay Updated
